Pro Research: Wall Street dives into Amgen's strategic shifts

ProResearch offers comprehensive research analysis based on insights from top Wall Street analysts. These articles will soon be accessible exclusively to InvestingPro subscribers. Seize the opportunity to become a Pro user now, taking advantage of our exclusive Cyber Monday promotion offering up to a 55% discount.

Amgen Inc (NASDAQ:)., a notable biopharmaceutical company, has been the subject of various Wall Street analyses, with a focus on its strategic acquisitions, pipeline developments, and competitive positioning within the biopharmaceutical industry. The company’s efforts in oncology, cardiovascular disease, bone health, neuroscience, nephrology, and inflammation have drawn attention from investors and analysts alike.

Company Overview

Amgen’s portfolio includes a range of treatments for serious illnesses, with a strong emphasis on oncology and precision medicine. The company has made significant strides in its product segments, including the recent acquisition of Horizon Therapeutics (NASDAQ:), which has bolstered its position in the market. Amgen’s pipeline features promising candidates such as Tarlatamab, AMG-193, LUMAKRAS, and Bemarituzumab, which are expected to drive future growth.

Market Performance

Analysts have highlighted Amgen’s robust oncology portfolio, noting that its drug Rocatinlimab has a narrow edge over competing treatments in phase 2 trials. The company’s stock has been subject to varying ratings, with some analysts expressing caution due to competition pressures and others maintaining a bullish outlook based on the company’s strong pipeline and strategic initiatives.

Strategic Acquisitions and Partnerships

The acquisition of Horizon has been a focal point for analysts, who see it as a strategic move that strengthens Amgen’s clinical progress narrative. The company is also actively engaging with the FDA, which could lead to positive developments for pipeline assets like Tarlatamab. Additionally, Amgen’s collaboration with IDEAYA Biosciences (NASDAQ:) on the combination strategy with IDYA’s MAT2A inhibitor, IDE397, is seen as a key differentiator in the market.

Financial Performance

Amgen’s financial results have generally met or exceeded expectations, with the company raising its full-year 2023 guidance for revenues and non-GAAP EPS. This reflects the inclusion of assets from the Horizon acquisition, such as Tepezza, Krystexxa, and Uplizna. The company has also committed to returning a significant portion of its non-GAAP net income to shareholders through dividends and share repurchases.

SWOT Analysis


  • Strong oncology and precision medicine portfolio.
  • Strategic acquisitions bolstering product offerings.
  • Active engagement with regulatory authorities.
  • Commitment to shareholder returns.


  • Competition pressures within the industry.
  • Underperformance of new product launches like Lumakras.
  • Concerns over meeting market expectations.


  • Pipeline assets with potential for market enthusiasm.
  • Expansion into obesity treatment areas.
  • Biosimilar approvals and launches offering growth potential.


  • Competitive drugs potentially having better safety profiles.
  • Uncertainty surrounding key product data readouts.
  • Risks associated with the transfer pricing case with the IRS.

Analysts Targets

  • Piper Sandler: Overweight with a price target of $288.00 (September 25, 2023).
  • Barclays (LON:) Capital Inc.: Underweight with a price target of $230.00 (November 01, 2023).
  • BMO Capital Markets: Market Perform with a price target of $286.00 (November 01, 2023).
  • Argus Research Company: BUY with a price target of $280.00 (September 18, 2023).
  • Truist Securities: BUY with a price target of $320.00 (November 02, 2023).

In conclusion, the information provided spans from September to November 2023, offering a comprehensive view of Amgen’s market position, strategic initiatives, and financial performance. Analysts have provided a range of perspectives, reflecting the complexity of the biopharmaceutical industry and the various factors that influence company valuation.

InvestingPro Insights

Amgen Inc. has been a beacon of consistency in the biopharmaceutical industry, and recent data from InvestingPro underscores this narrative. With a focus on its strategic acquisitions and robust pipeline, the company has maintained a strong market presence, as reflected in the latest metrics.

InvestingPro Data highlights Amgen’s substantial market capitalization of $141.63 billion, showcasing its significant scale within the industry. The company’s P/E ratio stands at a notable 18.78, indicating investor confidence in its earnings capacity. Moreover, Amgen’s revenue growth over the last twelve months as of Q3 2023 was 1.91%, demonstrating its ability to expand amidst a competitive landscape.

InvestingPro Tips reveal that Amgen’s revenue growth has been accelerating, which aligns with the company’s strategic acquisitions and could be a harbinger of sustained future growth. Additionally, Amgen yields a high return on invested capital, suggesting efficient use of funds in generating profits. This is particularly relevant to investors looking for companies with prudent capital allocation strategies.

For those seeking deeper insights, InvestingPro offers additional tips, with a total of 15 valuable pieces of analysis available exclusively to subscribers. Notably, the InvestingPro subscription is currently available at a special Cyber Monday sale, offering up to a 55% discount, providing investors an opportune moment to access these comprehensive insights.

As Amgen continues to navigate the biopharmaceutical terrain with strategic precision, the InvestingPro platform remains a valuable resource for real-time data and expert analysis to help investors make informed decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


This website uses cookies. By continuing to use this site, you accept our use of cookies.